Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price traded up 25% during trading on Tuesday . The stock traded as high as C$0.03 and last traded at C$0.03. 115,000 shares traded hands during mid-day trading, an increase of 131% from the average session volume of 49,707 shares. The stock had previously closed at C$0.02.
Quest PharmaTech Stock Performance
The stock’s fifty day moving average price is C$0.03 and its two-hundred day moving average price is C$0.04. The company has a market cap of C$4.23 million, a P/E ratio of -0.25 and a beta of 0.29. The company has a debt-to-equity ratio of 1.51, a quick ratio of 0.52 and a current ratio of 0.26.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Recommended Stories
- Five stocks we like better than Quest PharmaTech
- Consumer Staples Stocks, Explained
- Garmin Navigates to New Highs Driven By Wearables Trend
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What is an Earnings Surprise?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
